Navigation Links
MacuCLEAR, Inc. to Present at OneMedForum New York 2011 and at the 2011 BIO Business Forum During the Annual BIO International Convention in Washington, D.C.

PLANO, Texas, June 16, 2011 /PRNewswire/ -- MacuCLEAR, Inc., a specialty clinical stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today that Philip G. Ralston, president and CEO, will be presenting at OneMedForum New York 2011 on Thursday, June 23, 2011 at 11:30 a.m. EDT at The Roosevelt Hotel in New York City.  

OneMedForum will focus on critical success factors for building companies internationally.  In addition to presentations by more than 70 emerging medical technology companies, delegates will gain insights in the critical areas of regulatory approval, reimbursement and distribution and sales organizations in the EU and U.S.

Concurrently, Mr. Ralston will also present at the 2011 BIO Business Forum during the annual BIO International Convention at the Walter E. Washington Convention Center in Washington, D.C.  Mr. Ralston's presentation will be given on Wednesday, June 29, 2011 at 9:15 a.m. EDT in the Adams Morgan Room.  The presentation will include an overview of the company with emphasis on the lead proprietary compound, MC-1101, which is being developed for the treatment of the dry form of age-related macular degeneration (AMD).

The BIO Business Forum is a unique platform for biotechnology and pharmaceutical companies, academic research institutions and investors from around the world to gather and discuss strategic opportunities.  This forum is featured within the BIO International Convention, the largest global event for the biotechnology industry, offering networking and partnering opportunities with policymakers, scientists, CEOs and newsmakers and hundreds of sessions covering biotech trends, policy issues and technological innovations.

About MacuCLEAR, Inc.

MacuCLEAR, Inc. is a clinical-stage specialty pharmaceutical company focused on developing innovative treatments for vascular and retinal diseases of the eye.  Its lead compound MC-1101 is a novel, topically delivered eye drop drug for treating and stopping the progression of age-related macular degeneration (AMD) from the early-stage (Dry AMD) to the late-stage (Wet AMD) by improving ocular blood flow.

The active ingredient of MC-1101 has been previously approved by the FDA as an oral antihypertensive drug.  MC-1101 has been granted 505 (b) 2 status and has formal Fast Track designation by the FDA.  In addition to MC-1101, MacuCLEAR's portfolio includes 11 compounds that are being developed for diabetic retinopathy, second-generation treatment for AMD and other vascular diseases of the eye.

George C.Y. Chiou, Ph.D., who led the development of Timolol, a pioneering treatment for glaucoma, invented this technology at Texas A&M University.

Founded in 2006, MacuCLEAR is a privately held Plano, TX-based company.  For additional information, please visit

About Age-Related Macular Degeneration

AMD is the leading cause for blindness in the world in people 50 and older.  Dry AMD afflicts 90 percent of AMD sufferers and currently has no approved drug treatments.  

Media Contact:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach,
Claire Sojda,

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use
2. NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society
3. Dendreon Announces Webcast Presentation at NASDAQ OMX 26th Investor Program
4. NeoStem to Present at Two Investor Events This Month
5. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
6. Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings
7. PAREXEL International to Present at Wells Fargo Healthcare Conference
8. Spherix to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
9. Sono-Tek to Present Scientific Paper on Food Safety at the IFT, as E. Coli Outbreak Affects Europes Food Supply
10. Masimo to Present at William Blair & Company 31st Annual Growth Stock Conference
11. IDEXX Laboratories to Present at William Blair 31st Annual Growth Stock Conference
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software ... events in five states to develop and pitch their BIG ideas to improve health ... state are competing for votes to win the title of SAP's Teen Innovator, an ...
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual ... 11:00 a.m. Israel time, at the law offices ... Street, 36 th Floor, Tel Aviv, Israel . ... and Izhak Tamir to the Board of Directors; , ... , approval of an amendment to certain terms of options granted ...
(Date:11/24/2015)...  Twist Bioscience, a company focused on synthetic ... Bioscience chief executive officer, will present at the ... 2015 at 3:10 p.m. Eastern Time at The Lotte New ... --> --> About Twist ... on Twitter. Sign up to follow our Twitter ...
Breaking Biology Technology:
(Date:11/20/2015)... , November 20, 2015 ... company focused on the growing mobile commerce market and ... Gino Pereira , was recently interviewed on ... will air on this weekend on Bloomberg Europe ... America . --> NXTD ) ("NXT-ID" or ...
(Date:11/19/2015)... , Nov. 19, 2015  Based on its ... & Sullivan recognizes BIO-key with the 2015 Global Frost ... year, Frost & Sullivan presents this award to the ... catering to the needs of the market it serves. ... line meets and expands on customer base demands, the ...
(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
Breaking Biology News(10 mins):